Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 20/20 | 0.66 |
| ▸ | CNR2 | P34972 | 17/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8512219 | 1.00 | CNR1 (0.66) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL8509801 | 0.92 | CNR1 (0.67) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL8509797 | 0.92 | CNR1 (0.67) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL8509729 | 0.91 | CNR1 (0.66) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL8509727 | 0.91 | CNR1 (0.66) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL8512500 | 0.91 | CNR1 (0.66) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL8512503 | 0.91 | CNR1 (0.66) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL8514382 | 0.91 | CNR1 (0.66) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL8514386 | 0.91 | CNR1 (0.66) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL8510495 | 0.90 | CNR1 (0.67) | CNR1CNR2CYP2D6CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | MERCK & CO., INC. (US) | 2012-05-31 | — | — | US | claimed |
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | MERCK & CO., INC. (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | CNR1, CNR2, FAAH | CNR1 1/4885CNR2 2/4885CYP2D6 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.